Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio che confronta la combinazione di pembrolizumab e sacituzumab Govitecan con il solo sacituzumab Govitecan nel trattamento del cancro uroteliale avanzato

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio randomizzato di fase III su pembrolizumab in combinazione con sacituzumab Govitecan vs sacituzumab Govitecan da solo nel cancro uroteliale avanzato resistente agli anti-PD(L)1

This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVE:

I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.

SECONDARY OBJECTIVES:

I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.

II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.

III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.

IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.

V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:

I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.

II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.

III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.

IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.

V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.

ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.

After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.

Tipo di studio

Interventistico

Iscrizione (Stimato)

320

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85004
    • California
      • Irvine, California, Stati Uniti, 92612
        • Reclutamento
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-827-8839
          • Email: ucstudy@uci.edu
        • Investigatore principale:
          • Nataliya Mar
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-827-8839
          • Email: ucstudy@uci.edu
        • Investigatore principale:
          • Nataliya Mar
    • Florida
      • Gainesville, Florida, Stati Uniti, 32610
        • Reclutamento
        • UF Health Cancer Institute - Gainesville
        • Investigatore principale:
          • Daniel V. Araujo
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 352-273-8010
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital/Winship Cancer Institute
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-778-1868
        • Investigatore principale:
          • Jacqueline T. Brown
      • Atlanta, Georgia, Stati Uniti, 30308
        • Reclutamento
        • Emory University Hospital Midtown
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-946-7447
        • Investigatore principale:
          • Jacqueline T. Brown
      • Atlanta, Georgia, Stati Uniti, 30342
        • Reclutamento
        • Emory Saint Joseph's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-851-7115
        • Investigatore principale:
          • Jacqueline T. Brown
    • Idaho
      • Coeur d'Alene, Idaho, Stati Uniti, 83814
        • Reclutamento
        • Kootenai Health - Coeur d'Alene
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Post Falls, Idaho, Stati Uniti, 83854
        • Reclutamento
        • Kootenai Clinic Cancer Services - Post Falls
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Sandpoint, Idaho, Stati Uniti, 83864
        • Reclutamento
        • Kootenai Clinic Cancer Services - Sandpoint
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • University of Illinois
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 312-355-3046
        • Investigatore principale:
          • Karine Tawagi
      • Danville, Illinois, Stati Uniti, 61832
        • Reclutamento
        • Carle at The Riverfront
        • Investigatore principale:
          • Priyank P. Patel
        • Contatto:
      • Decatur, Illinois, Stati Uniti, 62526
        • Reclutamento
        • Cancer Care Specialists of Illinois - Decatur
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Decatur, Illinois, Stati Uniti, 62526
        • Reclutamento
        • Decatur Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Effingham, Illinois, Stati Uniti, 62401
        • Reclutamento
        • Carle Physician Group-Effingham
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
      • Effingham, Illinois, Stati Uniti, 62401
        • Reclutamento
        • Crossroads Cancer Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Mattoon, Illinois, Stati Uniti, 61938
        • Reclutamento
        • Carle Physician Group-Mattoon/Charleston
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
      • Normal, Illinois, Stati Uniti, 61761
        • Reclutamento
        • Carle BroMenn Medical Center
        • Investigatore principale:
          • Priyank P. Patel
        • Contatto:
      • Normal, Illinois, Stati Uniti, 61761
        • Reclutamento
        • Carle Cancer Institute Normal
        • Investigatore principale:
          • Priyank P. Patel
        • Contatto:
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Reclutamento
        • Cancer Care Center of O'Fallon
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Reclutamento
        • HSHS Saint Elizabeth's Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Shiloh, Illinois, Stati Uniti, 62269
        • Reclutamento
        • Memorial Hospital East
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • Springfield, Illinois, Stati Uniti, 62702
        • Reclutamento
        • Southern Illinois University School of Medicine
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 217-545-7929
      • Springfield, Illinois, Stati Uniti, 62702
        • Reclutamento
        • Springfield Clinic
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-444-7541
      • Springfield, Illinois, Stati Uniti, 62781
        • Reclutamento
        • Springfield Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Urbana, Illinois, Stati Uniti, 61801
        • Reclutamento
        • Carle Cancer Center
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
    • Iowa
      • Ames, Iowa, Stati Uniti, 50010
        • Reclutamento
        • Mary Greeley Medical Center
        • Investigatore principale:
          • Joseph J. Merchant
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-956-4132
      • Ames, Iowa, Stati Uniti, 50010
        • Reclutamento
        • McFarland Clinic - Ames
        • Investigatore principale:
          • Joseph J. Merchant
        • Contatto:
      • Boone, Iowa, Stati Uniti, 50036
        • Sospeso
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Reclutamento
        • Mercy Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 319-365-4673
        • Investigatore principale:
          • Deborah W. Wilbur
      • Cedar Rapids, Iowa, Stati Uniti, 52403
        • Reclutamento
        • Oncology Associates at Mercy Medical Center
        • Investigatore principale:
          • Deborah W. Wilbur
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 319-363-2690
      • Fort Dodge, Iowa, Stati Uniti, 50501
        • Reclutamento
        • McFarland Clinic - Trinity Cancer Center
        • Investigatore principale:
          • Joseph J. Merchant
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-956-4132
      • Jefferson, Iowa, Stati Uniti, 50129
        • Sospeso
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Stati Uniti, 50158
        • Reclutamento
        • McFarland Clinic - Marshalltown
        • Investigatore principale:
          • Joseph J. Merchant
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-956-4132
    • Kansas
      • Hays, Kansas, Stati Uniti, 67601
        • Reclutamento
        • HaysMed
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 785-623-5774
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • University of Kansas Cancer Center
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Lawrence, Kansas, Stati Uniti, 66044
        • Reclutamento
        • Lawrence Memorial Hospital
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Olathe, Kansas, Stati Uniti, 66061
        • Reclutamento
        • The University of Kansas Cancer Center - Olathe
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Overland Park, Kansas, Stati Uniti, 66210
        • Reclutamento
        • University of Kansas Cancer Center-Overland Park
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Salina, Kansas, Stati Uniti, 67401
        • Reclutamento
        • Salina Regional Health Center
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Topeka, Kansas, Stati Uniti, 66606
        • Reclutamento
        • University of Kansas Health System Saint Francis Campus
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 785-295-8000
      • Westwood, Kansas, Stati Uniti, 66205
        • Reclutamento
        • University of Kansas Hospital-Westwood Cancer Center
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • The James Graham Brown Cancer Center at University of Louisville
        • Investigatore principale:
          • Rohit Kumar
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 502-562-3429
      • Louisville, Kentucky, Stati Uniti, 40245
        • Reclutamento
        • UofL Health Medical Center Northeast
        • Investigatore principale:
          • Rohit Kumar
        • Contatto:
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70809
        • Reclutamento
        • Louisiana Hematology Oncology Associates LLC
        • Contatto:
        • Investigatore principale:
          • Scott E. Delacroix
      • Metairie, Louisiana, Stati Uniti, 70002
        • Reclutamento
        • Mary Bird Perkins Cancer Center - Metairie
        • Investigatore principale:
          • Scott E. Delacroix
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 504-584-6990
    • Massachusetts
      • Worcester, Massachusetts, Stati Uniti, 01655
        • Reclutamento
        • UMass Memorial Medical Center - University Campus
        • Contatto:
        • Investigatore principale:
          • Kriti Mittal
    • Michigan
      • Brighton, Michigan, Stati Uniti, 48114
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Canton, Michigan, Stati Uniti, 48188
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Chelsea, Michigan, Stati Uniti, 48118
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Lansing, Michigan, Stati Uniti, 48912
        • Reclutamento
        • University of Michigan Health - Sparrow Lansing
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Livonia, Michigan, Stati Uniti, 48154
        • Reclutamento
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Pontiac, Michigan, Stati Uniti, 48341
        • Reclutamento
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
      • Ypsilanti, Michigan, Stati Uniti, 48197
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contatto:
        • Investigatore principale:
          • Houssam Y. Hariri
    • Minnesota
      • Brainerd, Minnesota, Stati Uniti, 56401
        • Reclutamento
        • Essentia Health Saint Joseph's Medical Center
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Coon Rapids, Minnesota, Stati Uniti, 55433
        • Reclutamento
        • Mercy Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Deer River, Minnesota, Stati Uniti, 56636
        • Reclutamento
        • Essentia Health - Deer River Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Duluth, Minnesota, Stati Uniti, 55805
        • Reclutamento
        • Essentia Health Cancer Center
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Fairview Southdale Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Minnesota Oncology - Edina
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Hibbing, Minnesota, Stati Uniti, 55746
        • Reclutamento
        • Essentia Health Hibbing Clinic
        • Investigatore principale:
          • Bret E. Friday
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 218-786-3308
      • Marshall, Minnesota, Stati Uniti, 56258
        • Reclutamento
        • Avera Cancer Institute at Marshall
        • Contatto:
        • Investigatore principale:
          • Ryan A. Vaca
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Reclutamento
        • Abbott-Northwestern Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Saint Louis Park, Minnesota, Stati Uniti, 55416
        • Reclutamento
        • Park Nicollet Clinic - Saint Louis Park
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Saint Paul, Minnesota, Stati Uniti, 55101
        • Reclutamento
        • Regions Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Saint Paul, Minnesota, Stati Uniti, 55102
        • Reclutamento
        • United Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Sandstone, Minnesota, Stati Uniti, 55072
        • Reclutamento
        • Essentia Health Sandstone
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • Virginia, Minnesota, Stati Uniti, 55792
        • Reclutamento
        • Essentia Health Virginia Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
    • Missouri
      • Cape Girardeau, Missouri, Stati Uniti, 63703
        • Reclutamento
        • Saint Francis Medical Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 573-334-2230
          • Email: sfmc@sfmc.net
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Reclutamento
        • Siteman Cancer Center at Saint Peters Hospital
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Reclutamento
        • Siteman Cancer Center at West County Hospital
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • Farmington, Missouri, Stati Uniti, 63640
        • Reclutamento
        • Parkland Health Center - Farmington
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • Kansas City, Missouri, Stati Uniti, 64154
        • Reclutamento
        • University of Kansas Cancer Center - North
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Kansas City, Missouri, Stati Uniti, 64108
        • Reclutamento
        • University Health Truman Medical Center
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 816-404-4375
      • Kansas City, Missouri, Stati Uniti, 64116
        • Reclutamento
        • University of Kansas Cancer Center - Briarcliff
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 913-588-3671
      • Lee's Summit, Missouri, Stati Uniti, 64064
        • Reclutamento
        • University of Kansas Cancer Center - Lee's Summit
        • Investigatore principale:
          • Saqib Abbasi
        • Contatto:
      • Sainte Genevieve, Missouri, Stati Uniti, 63670
        • Reclutamento
        • Sainte Genevieve County Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • St Louis, Missouri, Stati Uniti, 63129
        • Reclutamento
        • Siteman Cancer Center-South County
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • St Louis, Missouri, Stati Uniti, 63136
        • Reclutamento
        • Siteman Cancer Center at Christian Hospital
        • Contatto:
        • Investigatore principale:
          • Melissa A. Reimers
      • St Louis, Missouri, Stati Uniti, 63131
        • Reclutamento
        • Missouri Baptist Medical Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
      • Sullivan, Missouri, Stati Uniti, 63080
        • Reclutamento
        • Missouri Baptist Sullivan Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-996-5569
    • Montana
      • Anaconda, Montana, Stati Uniti, 59711
        • Reclutamento
        • Community Hospital of Anaconda
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Billings, Montana, Stati Uniti, 59101
        • Reclutamento
        • Billings Clinic Cancer Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Bozeman, Montana, Stati Uniti, 59715
        • Reclutamento
        • Bozeman Health Deaconess Hospital
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Great Falls, Montana, Stati Uniti, 59405
        • Reclutamento
        • Benefis Sletten Cancer Institute
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Kalispell, Montana, Stati Uniti, 59901
        • Reclutamento
        • Logan Health Medical Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
      • Missoula, Montana, Stati Uniti, 59804
        • Reclutamento
        • Community Medical Center
        • Investigatore principale:
          • John M. Schallenkamp
        • Contatto:
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03756
        • Reclutamento
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Contatto:
        • Investigatore principale:
          • Jacob B. Reibel
    • New Jersey
      • Livingston, New Jersey, Stati Uniti, 07039
        • Reclutamento
        • Cooperman Barnabas Medical Center
        • Investigatore principale:
          • Biren Saraiya
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 973-322-5200
      • Long Branch, New Jersey, Stati Uniti, 07740
        • Reclutamento
        • Monmouth Medical Center
        • Contatto:
        • Investigatore principale:
          • Biren Saraiya
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Reclutamento
        • Rutgers Cancer Institute of New Jersey
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-7356
        • Investigatore principale:
          • Biren Saraiya
      • Newark, New Jersey, Stati Uniti, 07101
        • Reclutamento
        • Rutgers New Jersey Medical School
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-7356
        • Investigatore principale:
          • Biren Saraiya
      • Somerville, New Jersey, Stati Uniti, 08876
        • Reclutamento
        • Robert Wood Johnson University Hospital Somerset
        • Investigatore principale:
          • Biren Saraiya
        • Contatto:
      • Toms River, New Jersey, Stati Uniti, 08755
        • Reclutamento
        • Community Medical Center
        • Investigatore principale:
          • Biren Saraiya
        • Contatto:
    • New York
      • Buffalo, New York, Stati Uniti, 14263
        • Reclutamento
        • Roswell Park Cancer Institute
        • Contatto:
        • Investigatore principale:
          • Ellis G. Levine
      • Stony Brook, New York, Stati Uniti, 11794
        • Reclutamento
        • Stony Brook University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-862-2215
        • Investigatore principale:
          • Judy Huang
      • Williamsville, New York, Stati Uniti, 14221
        • Reclutamento
        • Roswell Park Amherst Center
        • Contatto:
        • Investigatore principale:
          • Ellis G. Levine
    • North Carolina
      • Hendersonville, North Carolina, Stati Uniti, 28791
        • Reclutamento
        • Margaret R Pardee Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • John K. Hill
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58103
        • Reclutamento
        • Essentia Health Cancer Center-South University Clinic
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • Ohio State University Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Yuanquan Yang
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • University of Oklahoma Health Sciences Center
        • Contatto:
        • Investigatore principale:
          • Adanma Anji Ayanambakkam Attanathi
    • Pennsylvania
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Reclutamento
        • Geisinger Medical Center
        • Investigatore principale:
          • Sorab Gupta
        • Contatto:
      • Dickson City, Pennsylvania, Stati Uniti, 18519
        • Reclutamento
        • Geisinger Cancer Center Dickson City
        • Investigatore principale:
          • Sorab Gupta
        • Contatto:
      • Erie, Pennsylvania, Stati Uniti, 16505
        • Reclutamento
        • UPMC Hillman Cancer Center Erie
        • Investigatore principale:
          • Leonard J. Appleman
        • Contatto:
      • Erie, Pennsylvania, Stati Uniti, 16544
        • Reclutamento
        • Saint Vincent Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 814-452-5000
        • Investigatore principale:
          • Alexander Helfand
      • Greensburg, Pennsylvania, Stati Uniti, 15601
        • Reclutamento
        • UPMC Cancer Centers - Arnold Palmer Pavilion
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 724-838-1900
        • Investigatore principale:
          • Leonard J. Appleman
      • Harrisburg, Pennsylvania, Stati Uniti, 17109
        • Reclutamento
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
        • Contatto:
        • Investigatore principale:
          • Leonard J. Appleman
      • Hershey, Pennsylvania, Stati Uniti, 17033-0850
        • Reclutamento
        • Penn State Milton S Hershey Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 717-531-3779
          • Email: CTO@hmc.psu.edu
        • Investigatore principale:
          • Monika Joshi
      • Indiana, Pennsylvania, Stati Uniti, 15701
        • Reclutamento
        • IRMC Cancer Center
        • Contatto:
        • Investigatore principale:
          • Leonard J. Appleman
      • Jefferson Hills, Pennsylvania, Stati Uniti, 15025
        • Reclutamento
        • Jefferson Hospital
        • Contatto:
        • Investigatore principale:
          • Alexander Helfand
      • Lewisburg, Pennsylvania, Stati Uniti, 17837
        • Reclutamento
        • Geisinger Medical Oncology-Lewisburg
        • Investigatore principale:
          • Sorab Gupta
        • Contatto:
      • Mechanicsburg, Pennsylvania, Stati Uniti, 17050
        • Reclutamento
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
        • Contatto:
        • Investigatore principale:
          • Leonard J. Appleman
      • Monroeville, Pennsylvania, Stati Uniti, 15146
        • Reclutamento
        • Forbes Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-858-7746
        • Investigatore principale:
          • Alexander Helfand
      • Monroeville, Pennsylvania, Stati Uniti, 15146
        • Reclutamento
        • UPMC Hillman Cancer Center - Monroeville
        • Investigatore principale:
          • Leonard J. Appleman
        • Contatto:
      • Natrona Heights, Pennsylvania, Stati Uniti, 15065
        • Reclutamento
        • Allegheny Valley Hospital
        • Contatto:
        • Investigatore principale:
          • Alexander Helfand
      • Pittsburgh, Pennsylvania, Stati Uniti, 15224
        • Reclutamento
        • West Penn Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-578-5000
        • Investigatore principale:
          • Alexander Helfand
      • Pittsburgh, Pennsylvania, Stati Uniti, 15215
        • Reclutamento
        • UPMC-Saint Margaret
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-784-4900
        • Investigatore principale:
          • Leonard J. Appleman
      • Pittsburgh, Pennsylvania, Stati Uniti, 15237
        • Reclutamento
        • UPMC-Passavant Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-367-6454
        • Investigatore principale:
          • Leonard J. Appleman
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Reclutamento
        • Allegheny General Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-284-2000
        • Investigatore principale:
          • Alexander Helfand
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • Reclutamento
        • UPMC Hillman Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-647-8073
        • Investigatore principale:
          • Leonard J. Appleman
      • Seneca, Pennsylvania, Stati Uniti, 16346
        • Reclutamento
        • UPMC Cancer Center at UPMC Northwest
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 814-676-7900
        • Investigatore principale:
          • Leonard J. Appleman
      • Uniontown, Pennsylvania, Stati Uniti, 15401
        • Reclutamento
        • UPMC Cancer Center-Uniontown
        • Contatto:
        • Investigatore principale:
          • Leonard J. Appleman
      • Washington, Pennsylvania, Stati Uniti, 15301
        • Reclutamento
        • UPMC Cancer Center-Washington
        • Contatto:
        • Investigatore principale:
          • Leonard J. Appleman
      • West Reading, Pennsylvania, Stati Uniti, 19611
        • Reclutamento
        • Reading Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 610-988-9323
        • Investigatore principale:
          • Terrence P. Cescon
      • Wexford, Pennsylvania, Stati Uniti, 15090
        • Reclutamento
        • Wexford Health and Wellness Pavilion
        • Contatto:
        • Investigatore principale:
          • Alexander Helfand
      • Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
        • Reclutamento
        • Geisinger Wyoming Valley/Henry Cancer Center
        • Contatto:
        • Investigatore principale:
          • Sorab Gupta
    • South Dakota
      • Aberdeen, South Dakota, Stati Uniti, 57401
        • Reclutamento
        • Avera Cancer Institute-Aberdeen
        • Contatto:
        • Investigatore principale:
          • Ryan A. Vaca
      • Mitchell, South Dakota, Stati Uniti, 57301
        • Reclutamento
        • Avera Cancer Institute - Mitchell
        • Contatto:
        • Investigatore principale:
          • Ryan A. Vaca
      • Pierre, South Dakota, Stati Uniti, 57501
        • Reclutamento
        • Avera Cancer Institute at Pierre
        • Contatto:
        • Investigatore principale:
          • Ryan A. Vaca
      • Sioux Falls, South Dakota, Stati Uniti, 57105
        • Reclutamento
        • Avera Cancer Institute
        • Contatto:
        • Investigatore principale:
          • Ryan A. Vaca
      • Yankton, South Dakota, Stati Uniti, 57078
        • Reclutamento
        • Avera Cancer Institute at Yankton
        • Investigatore principale:
          • Ryan A. Vaca
        • Contatto:
    • Texas
      • Baytown, Texas, Stati Uniti, 77521
        • Reclutamento
        • Houston Methodist San Jacinto Hospital
        • Contatto:
        • Investigatore principale:
          • Patrick E. Prath
      • Cypress, Texas, Stati Uniti, 77429
        • Reclutamento
        • Houston Methodist Cypress Hospital
        • Contatto:
        • Investigatore principale:
          • Patrick E. Prath
      • Dallas, Texas, Stati Uniti, 75390
        • Reclutamento
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Contatto:
        • Investigatore principale:
          • Suzanne M. Cole
      • Dallas, Texas, Stati Uniti, 75235
        • Reclutamento
        • Parkland Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • Suzanne M. Cole
      • Dallas, Texas, Stati Uniti, 75237
        • Reclutamento
        • UT Southwestern Simmons Cancer Center - RedBird
        • Investigatore principale:
          • Suzanne M. Cole
        • Contatto:
      • Fort Worth, Texas, Stati Uniti, 76104
        • Reclutamento
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • Contatto:
        • Investigatore principale:
          • Suzanne M. Cole
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Houston Methodist Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 713-790-2700
        • Investigatore principale:
          • Patrick E. Prath
      • Houston, Texas, Stati Uniti, 77070
        • Reclutamento
        • Methodist Willowbrook Hospital
        • Contatto:
        • Investigatore principale:
          • Patrick E. Prath
      • Houston, Texas, Stati Uniti, 77094
        • Reclutamento
        • Houston Methodist West Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 832-522-2873
        • Investigatore principale:
          • Patrick E. Prath
      • Nassau Bay, Texas, Stati Uniti, 77058
        • Reclutamento
        • Houston Methodist Saint John Hospital
        • Contatto:
        • Investigatore principale:
          • Patrick E. Prath
      • Richardson, Texas, Stati Uniti, 75080
        • Reclutamento
        • UT Southwestern Clinical Center at Richardson/Plano
        • Contatto:
        • Investigatore principale:
          • Suzanne M. Cole
      • Sugar Land, Texas, Stati Uniti, 77479
        • Reclutamento
        • Houston Methodist Sugar Land Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 281-242-2873
        • Investigatore principale:
          • Patrick E. Prath
      • The Woodlands, Texas, Stati Uniti, 77385
        • Reclutamento
        • Houston Methodist The Woodlands Hospital
        • Contatto:
        • Investigatore principale:
          • Patrick E. Prath
    • Vermont
      • Berlin Corners, Vermont, Stati Uniti, 05602
        • Reclutamento
        • Central Vermont Medical Center/National Life Cancer Treatment
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 802-225-5400
        • Investigatore principale:
          • Rahul Anil
      • Burlington, Vermont, Stati Uniti, 05401
        • Reclutamento
        • University of Vermont Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 802-656-4101
          • Email: rpo@uvm.edu
        • Investigatore principale:
          • Rahul Anil
      • Burlington, Vermont, Stati Uniti, 05405
        • Reclutamento
        • University of Vermont and State Agricultural College
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 802-656-8990
          • Email: rpo@uvm.edu
        • Investigatore principale:
          • Rahul Anil
      • Saint Johnsbury, Vermont, Stati Uniti, 05819
        • Reclutamento
        • Dartmouth Cancer Center - North
        • Contatto:
        • Investigatore principale:
          • Jacob B. Reibel
    • Virginia
      • Fredericksburg, Virginia, Stati Uniti, 22408
        • Reclutamento
        • Hematology Oncology Associates of Fredericksburg Inc
        • Contatto:
        • Investigatore principale:
          • Asit K. Paul
      • Richmond, Virginia, Stati Uniti, 23229
        • Reclutamento
        • Virginia Cancer Institute
        • Contatto:
        • Investigatore principale:
          • Asit K. Paul
      • Richmond, Virginia, Stati Uniti, 23235
        • Reclutamento
        • VCU Massey Cancer Center at Stony Point
        • Contatto:
        • Investigatore principale:
          • Asit K. Paul
      • Richmond, Virginia, Stati Uniti, 23298
        • Reclutamento
        • VCU Massey Comprehensive Cancer Center
        • Investigatore principale:
          • Asit K. Paul
        • Contatto:
    • Washington
      • Bellevue, Washington, Stati Uniti, 98004
        • Reclutamento
        • FHCC Overlake
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 425-454-2148
        • Investigatore principale:
          • Mikhail G. Perlov
      • Kirkland, Washington, Stati Uniti, 98034
        • Reclutamento
        • FHCC at EvergreenHealth
        • Investigatore principale:
          • Prakash Varadarajan
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 425-899-6000
      • Seattle, Washington, Stati Uniti, 98195
        • Reclutamento
        • University of Washington Medical Center - Montlake
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-804-8824
        • Investigatore principale:
          • Petros Grivas
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Fred Hutchinson Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-804-8824
        • Investigatore principale:
          • Petros Grivas
      • Seattle, Washington, Stati Uniti, 98133
        • Reclutamento
        • FHCC at Northwest Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 206-606-5800
        • Investigatore principale:
          • Nellowe Candelario
    • West Virginia
      • Charleston, West Virginia, Stati Uniti, 25304
        • Reclutamento
        • Vandalia Health/CAMC Institute for Academic Medicine
        • Investigatore principale:
          • Kok Hoe Chan
        • Contatto:
    • Wisconsin
      • Appleton, Wisconsin, Stati Uniti, 54911
        • Reclutamento
        • ThedaCare Regional Cancer Center
        • Contatto:
        • Investigatore principale:
          • Joyce Philip
      • Ashland, Wisconsin, Stati Uniti, 54806
        • Reclutamento
        • Duluth Clinic Ashland
        • Contatto:
        • Investigatore principale:
          • Bret E. Friday
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Reclutamento
        • Gundersen Lutheran Medical Center
        • Contatto:
        • Investigatore principale:
          • Kurt Oettel
      • New Richmond, Wisconsin, Stati Uniti, 54017
        • Reclutamento
        • Cancer Center of Western Wisconsin
        • Contatto:
        • Investigatore principale:
          • David M. King

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patient must be ≥ 18 years of age

  • Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

  • Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer

  • Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded

  • Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization

  • Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy

  • Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy

    • NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
    • NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
  • Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose

  • For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion

  • Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician

  • Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan

  • Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases

  • Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities

  • Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion

    • NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.

    • Examples of non-clinically significant laboratory abnormalities include, but are not limited to:

      • Lymphopenia or monopenia
      • Lymphocytosis or monocytosis
      • Increase in amylase or lipase with no clinical correlation
      • Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
    • NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization

  • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment

  • Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment

  • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

  • Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)

  • Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)

  • Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)

  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)

  • Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)

  • Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)

  • Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm

    • NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization

  • Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible

  • Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible

  • Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.

    • NOTE: Sites cannot translate the associated HRQOL forms

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm I (TPC chemotherapy)

Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Given IV

Altri nomi:
  • CDDP
  • Cis-diamminedicloridoroplatino
  • Cismaplat
  • Cisplatino
  • Neoplatino
  • Platinolo
  • Abiplatino
  • Blastolem
  • Briplatino
  • Cis-diammina-dicloroplatino
  • Cis-diamminodicloro Platino (II)
  • Cis-diamminedicloroplatino
  • Cis-dicloroammina Platino (II)
  • Diammina dicloruro di cis-platino
  • Cis-platino
  • Cis-platino II
  • Diammina dicloruro di cis-platino II
  • Cisplatile
  • Citoplatino
  • Citosina
  • DDP
  • Lederplatino
  • Metaplatino
  • Cloruro di Peyrone
  • Sale di Peyrone
  • Placis
  • Plastistil
  • Platamina
  • Platiblastina
  • Platiblastin-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platino
  • Diamminodicloruro di platino
  • Platirano
  • Platistin
  • Platosina

Given IV

Altri nomi:
  • Taxotere
  • Doccad
  • RP56976
  • Taxotere concentrato per iniezione
  • RP 56976
  • RP-56976

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Ancillary studies

Given IV

Altri nomi:
  • dFdCyd
  • dFdC
  • Difluorodesossicitidina
Sperimentale: Arm II (pembrolizumab, sacituzumab govitecan-hziy)

Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Undergo CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Ancillary studies

Given IV

Altri nomi:
  • Chiavetruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • MK3475
  • SCH-900475
  • BCD-201
  • Pembrolizumab biosimilare BCD-201
  • Pembrolizumab biosimilare QL2107
  • QL2107
  • GME751
  • Pembrolizumab biosimilare GME751
  • SCH900475
  • Pembrolizumab biosimilare RPH-075
  • RPH 075
  • RPH-075
  • RPH075
  • Pembrolizumab Biosimilar SB27
  • SB 27
  • SB-27
  • SB27

Given IV

Altri nomi:
  • IMMU-132
  • Trodelvy
  • Sacituzumab Govitecan-hziy
  • Coniugato farmaco anticorpo hRS7-SN38
  • RS7-SN38
  • IMMU 132
  • IMMU132
  • RS7SN38

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall survival (OS)
Lasso di tempo: From randomization to death due to any cause, assessed up to 5 years

OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported.

From randomization to death due to any cause, assessed up to 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS)
Lasso di tempo: From randomization to the earlier progression or death due to any cause, assessed up to 5 years

PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported.

From randomization to the earlier progression or death due to any cause, assessed up to 5 years
Overall response rate (ORR)
Lasso di tempo: Up to 5 years

ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI.

Up to 5 years
Clinical benefit rate (CBR)
Lasso di tempo: Up to 5 years

CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI.

Up to 5 years
Duration of response (DOR)
Lasso di tempo: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years

DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported.

From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
Incidence of adverse events (AEs)
Lasso di tempo: Up to 30 days after last dose of study drug

AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%.

Up to 30 days after last dose of study drug

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
Lasso di tempo: At baseline and at 3, 6 and 12 months

Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score.

At baseline and at 3, 6 and 12 months
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
Lasso di tempo: At baseline and at 3, 6 and 12 months

Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model.

At baseline and at 3, 6 and 12 months
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
Lasso di tempo: At baseline and at 3, 6 and 12 months

Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity.

At baseline and at 3, 6 and 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Monika Joshi, ECOG-ACRIN Cancer Research Group

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 dicembre 2025

Completamento primario (Stimato)

31 dicembre 2030

Completamento dello studio (Stimato)

31 dicembre 2030

Date di iscrizione allo studio

Primo inviato

26 luglio 2024

Primo inviato che soddisfa i criteri di controllo qualità

26 luglio 2024

Primo Inserito (Effettivo)

29 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2024-06208
  • U10CA180820 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2024-06208 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • EA8231 (Altro identificatore: CTEP)
  • EA8231 (Altro identificatore: ECOG-ACRIN Cancer Research Group)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .